1. INOVIO presents at H.C. Wainwright Global Investment Conference. 2. Presentation starts on September 5, 2025, via webcast. 3. Investors can meet INOVIO management for one-on-one discussions. 4. INO focuses on DNA medicines for HPV-associated diseases and cancer. 5. Conference may attract investor interest in INO's future prospects.
Participation in investor conferences often boosts visibility and market interest. Previous engagements have led to increased stock performance due to heightened investor engagement.
The conference increases INO's investor engagement, potentially improving stock performance. Greater visibility can prompt recent developments or news coverage, affecting investor perceptions.
The conference occurs soon, impacting INO's stock within weeks post-event through newfound investments. Historical data shows immediate stock responses to investor feedback obtained from such events.
PLYMOUTH MEETING, Pa., Aug. 25, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that a pre-recorded presentation from the Company will be available on demand as a part of the H.C. Wainwright 27th Annual Global Investment Conference in New York. During the conference, members of INOVIO's management team will also be conducting in-person one-on-one meetings with investors.
H.C. Wainwright 27th Annual Global Investment Conference
Presentation available: Beginning Friday, September 5, 2025, 7:00AM ET
Format: Pre-recorded webcast
Link: https://journey.ct.events/view/c0cc4d12-f619-4d58-878f-4ee305e4f2c2
The webcast will be available for 90 days at the link above or on the INOVIO Investor Relations Events page: https://ir.inovio.com/events-and-presentations/default.aspx.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505, investor.relations@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference-302536840.html
SOURCE INOVIO Pharmaceuticals, Inc.